|Brand name(s), other common name(s)||Revlimid®|
|How the drug is given||By mouth|
Indications and Usage
Lenalidomide is FDA approved to treat patients with:
- Multiple myeloma, in combination with dexamethasone
- Multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
- Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities
- Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
- Previously treated follicular lymphoma (FL), in combination with a rituximab product
- Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product
Limitations of Use: Revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials
Side effects needing medical attention
Arm or leg swelling; black, tarry stools; bleeding gums; blood in urine or stools; chest pain; chills; cough; convulsions; decreased urine or painful or difficult urination; difficult or labored breathing, shortness of breath or wheezing; dry mouth; fever; increased thirst; irregular heartbeat; loss of appetite; lower back or side pain; mood changes; muscle pain or cramps; nausea or vomiting; numbness or tingling in hands, feet or lips; pale skin; pinhead-sized red spots on skin; sore throat; sores, ulcers or white spots on lips or in mouth; swollen glands; tightness in chest; unusual bleeding or bruising; unusual tiredness or weakness.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.